Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections

Michael T. Halpern, Mary A. Cifaldi, Jordana K. Schmier

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.

Original languageEnglish (US)
Pages (from-to)217-223
Number of pages7
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume2
Issue number2
DOIs
StatePublished - Jan 1 2005

Keywords

  • Bronchitis
  • Chronic
  • Clarithromycin
  • Costs and cost analysis
  • Economic
  • Models
  • Pneumonia
  • Respiratory tract infections

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections'. Together they form a unique fingerprint.

  • Cite this